PRINCETON, N.J.--(BUSINESS WIRE)--Adare Pharmaceuticals, Inc. announced that Dr. Peter Richardson has joined the Company as Vice President, Research & Development and Chief Medical Officer. Dr. Richardson will be responsible for leading our Research and Development efforts worldwide and for the successful development of the Company’s pipeline.

“We are delighted to have Peter join the Adare team. His extensive experience in the successful development and approval of specialized pharmaceutical products and medical devices globally will be key to our organization, as we accelerate our development plans and implement our growth strategy,” said John Fraher, President and CEO of Adare Pharmaceuticals.

Dr. Richardson brings 30 years of medical practice, research and development experience in the pharmaceutical and medical device industry. Dr. Richardson has developed centers of excellence which enable product pipelines encompassing small molecules, biologics, novel formulations and medical devices. During his industry career he has managed programs leading to the submission and review of NDAs, sNDAs, BLAs and Marketing Authorization Applications in the US, Europe and Japan for over 20 marketed products.

He joins our team from Novartis Corporation where he was most recently the Chief Medical Officer for its eye care division Alcon. In this role he held multiple responsibilities including leading the company's clinical, regulatory and safety organizations globally and serving as its ad-interim head of research and development for its Pharmaceutical business.

Dr. Richardson is a physician with specialization in endocrinology, holding bachelors degrees of medical science (B.Med.Sci.), medicine and surgery (BM, BS) with honors from the University of Nottingham in the United Kingdom. He is a member of the Royal College of Physicians of the United Kingdom, MRCP (UK) and from whom he was also awarded a diploma in Pharmaceutical Medicine.

About Adare Pharmaceuticals

Adare is a global specialty pharmaceutical company inspired to improve the lives of patients whose treatment needs are not fully addressed by current medications. We use our unique combination of experience, proprietary capabilities, and resources to create meaningful products for them.

Our entrepreneurial and performance driven culture encourages us to take risks, identify promising ideas, and see those opportunities through to completion. Our collaborative spirit and dedication to developing strong partnerships provide Adare and our partners with significant advantages in competitive markets.

Adare is a high-growth company with a long history of success from concept through commercialization. Our ability to create differentiated drugs guides the identification and development of the novel products in our pipeline and our acquisition strategy.

For more information, visit www.adarepharma.com.